Fulgent buys CSI Laboratories to expand cancer testing capabilities
The acquisition of CSI will allow Fulgent to significantly expand its capabilities in molecular diagnostics and oncologic testing
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Aug 21
The acquisition of CSI will allow Fulgent to significantly expand its capabilities in molecular diagnostics and oncologic testing
10 Aug 21
The new facility will provide an engineer-to-engineer collaboration experience to customers for improved product performance
10 Aug 21
New test helps people understand their body's response to Covid vaccine
10 Aug 21
Pala Diagnostics will provide laboratory mobile concierge service for businesses, conventions, hospitality, and schools
09 Aug 21
The acquisition of Intersect ENT, which offers clinically proven PROPEL and SINUVA sinus implants that deliver an anti-inflammatory…
09 Aug 21
The partnership will also offer integrated data and clinical and operational insight services to hospitals and healthcare providers
09 Aug 21
The rapid portable test holds the capacity to identify SARS-CoV-2 antigen in people with active infections in two…
09 Aug 21
First commercial implantations of the HAART 200 Device for Bicuspid Aortic Valve repair performed by Professor Marek Jasinski…
09 Aug 21
New Test Kit Aids in Identifying the Presence of Cancerous or Precancerous Growths in the Colon Aims to…
09 Aug 21
Expanding patient access to incision-free Focused Ultrasound treatment